-
Two New Reports Show SX-682 Blocks Key Immunosuppressive Tumor Cells to Enhance Checkpoint Inhibitors and NK-Based Cell Immunotherapies
-Researchers at the Fred Hutchinson Cancer Research Center and the National Institutes of Health (NIH) independently showed SX-682 eradicates pivotal…
0
Archive for 2020
Syntrix Pharmaceuticals > 2020